Navigation Links
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Date:10/31/2011

e retention. Therefore, NUCYNTA® should not be used in patients susceptible to the effects of raised cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure. Opioid analgesics may obscure the clinical course of patients with head injury due to effects on pupillary response and consciousness. NUCYNTA® should be used with caution in patients with head injury, intracranial lesions, or other sources of preexisting increased intracranial pressure.
  • NUCYNTA® is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty. NUCYNTA® can be abused in a manner similar to other mu-opioid agonists, legal or illicit. This should be considered when prescribing or dispensing NUCYNTA® in situations where the physician or pharmacist is concerned about an increased risk of misuse and abuse. All patients treated with mu-opioid agonists require careful monitoring for signs of abuse and addiction. NUCYNTA® may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.
  • Experience with NUCYNTA® overdose is very limited. Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to reestablishment of a patent airway and institution of assisted or controlled ventilation when overdose of NUCYNTA® is suspected. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.
  • Patients should be cautioned that NUCYNTA® may impair the mental and/or physical abilities required for the performance of potentially hazardo
    '/>"/>

  • SOURCE Janssen Pharmaceuticals Research & Development
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
    2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
    3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
    4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
    5. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
    7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
    8. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
    9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
    10. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
    11. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... The North American dental lasers market ... to reach $90.7 million by 2019, at a CAGR of ... TOC of North America Dental Lasers Market for an analysis ... tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in ...
    (Date:5/22/2015)... 2015  The U.S. Food and Drug Administration,s ... first biosimilar product approved in the ... in the contract manufacturing organization (CMO) industry, according ... geared to the production of small-molecular drugs and ... The healthcare market research publisher,s report, Biopharmaceutical ...
    (Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
    Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
    (Date:5/26/2015)... (PRWEB) May 26, 2015 Carl W. ... Pinehurst Surgical Center in Pinehurst, N.C. have launched a ... surgery patients about chronic sinusitis and the benefits of ... can be used to determine if someone is a ... about symptoms and other factors that can contribute to ...
    (Date:5/25/2015)... May 26, 2015 Author Vincent N. Cefalu, ... people today are overweight, and many of them aren’t aware ... also knows that most people don’t realize the dangers of ... and man-made toxins that exist. There is also ... exactly how serious tobacco is.” , In “ A Doctor’s ...
    (Date:5/25/2015)... 26, 2015 The National ... Dr. Heather Stanley-Christian as a 2015-2016 inductee ... She is recognized with this prestigious distinction for ... networking organization exclusively for professional women, boasting more ... chapters. , "I'm pleased to welcome Heather into ...
    (Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... distributor of patented products, launches the Big Little Party ... to customize the perfect table that will suit their ... a whopping revenue of $646 billion this past year. ... a year industry" says Scott J. Cooper, CEO and ...
    (Date:5/25/2015)... According to a recently published report by ... external fixation market is driven by an increase in ... in infection prevention technologies. As the population ages, prevalence ... for the largest total number of bone fixation procedures ... As a result, the average selling price (ASP) of ...
    Breaking Medicine News(10 mins):Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3
    ... information about the disease in the Hispanic community , TUESDAY, ... will feature a storyline on diabetes in order to boost ... , The comic strip features a Hispanic teen named Baldo ... 30, Baldo will learn his father has diabetes. The teen ...
    ... ... to Improve Patient Experience , ... Scottsdale, AZ (Vocus) June 30, 2009 -- Carefx ... of integrated health services, has chosen the Fusionfx Solution Suite to deliver interoperability ...
    ... Drug Cards to Residents , , LINCOLN, Neb., June ... called the Nebraska Rx Card is being launched today. The ... will provide savings of up to 75% on prescription drugs ... to membership, no income requirements, and no age limitations. ...
    ... Calif., June 30 Hyperion Therapeutics, a privately held ... that address critical unmet needs in the areas of ... $60 million Series C financing. New investors Bay City ... and B investors Highland Capital Partners, NEA, and Sofinnova ...
    ... Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... products primarily for the respiratory and related markets, today ... 3000 Index following Russell Investments, reconstitution of its comprehensive ... 26, 2009. Cornerstone was also added to the ...
    ... International, Inc. (Pink Sheets: YOCM.PK) is pleased to ... L. acidophilus NCFM ... soft serve frozen yogurt with beneficial probiotics clinically ... , , (Photo: ...
    Cached Medicine News:Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 2Health News:Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 3Health News:Nebraska Prescription Assistance Program Launched 2Health News:Hyperion Therapeutics Raises $60 Million Series C 2Health News:Hyperion Therapeutics Raises $60 Million Series C 3Health News:Cornerstone Therapeutics Joins the Russell 3000(R) Index 2Health News:Cornerstone Therapeutics Joins the Russell 3000(R) Index 3Health News:Cornerstone Therapeutics Joins the Russell 3000(R) Index 4Health News:Cornerstone Therapeutics Joins the Russell 3000(R) Index 5Health News:YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System. 2Health News:YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System. 3Health News:YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System. 4
    HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel....
    ... For use in the percutaneous retrieval of ... or wire guides, and other foreign objects. ... snare around the lead body. It is delivered ... long, flexible 12 Fr cannula that is placed ...
    ... existing patented technologies such as Simtec ... with the new innovations of automated ... determination, and intelligent collision avoidance in ... treatment delivery with enhanced patient safety. ...
    Clinac EX Platinum accelerators offer all the high performance features of the EX series and come standard with the latest high-precision dose sculpting technology for advanced tumor control....
    Medicine Products: